Cybersecurity job postings in pharma industry up at 34 per cent CAGR since 2020: GlobalData, ET HealthWorld
New Delhi: In the pharmaceutical industry, there is currently a noticeable shift occurring where companies are giving greater importance to embracing emerging technologies and strict compliance measures to protect themselves against cyber threats and data breaches.The shift has led to a significant increase in the recruitment of professionals for various cybersecurity-related positions, such as those related to data, automation, security, compliance, risk management, and relationship management in the second quarter of 2023. According to data from GlobalData’s Job Analytics Database, this trend has seen a compound annual growth rate of 34 per cent since 2020.Furthermore, an examination of the Company Filing Analytics Database has shown that cybersecurity has been a prominent topic of discussion within the pharmaceutical industry in the second quarter of 2023, particularly as companies push for digital transformation.
“The growing digital engagement, coupled with the rising occurrence of data breaches, has prompted pharma companies to place a heightened emphasis on roles geared towards minimising enterprise risks. These roles aim to advocate privacy measures and develop cybersecurity strategies that enhance the comprehension of privacy-related risks linked to emerging technologies,” said Misa Singh, Business Fundamentals Analyst, GlobalData.
The “Associate General Counsel, Privacy” position at Gilead Sciences Inc. centers around providing guidance on the integration of new and emerging technologies and ensuring compliance with various initiatives aimed at minimising or mitigating risks as the company expands its digital presence. On the other hand, GSK plc’s “Assistant General Counsel, Privacy and Digital, Global R&D” role is primarily focused on advancing the global strategies related to digital, privacy, and cybersecurity within the U.S. branch of the business. Additionally, this role lends support to special projects as assigned, including but not limited to, handling matters related to CCPA and other U.S. state laws, addressing Brexit implications, Schrems II compliance, conducting Data Transfer Risk Assessments, ensuring compliance with HIPAA regulations, overseeing AI/ML initiatives, and managing Enterprise Tech Initiatives.The role of the “Director, Corporate Counsel – Technology Privacy” at Regeneron Pharmaceuticals Inc entails providing guidance on the adoption of emerging technologies such as IOT/E, generative AI, robotics, and machine learning while also understanding the privacy risks associated with these technologies, including tokenisation and data set integration.
In contrast, the “Sr. Director – Counsel – Consumer / Customer Operations” position at Eli Lilly and Co defines the requirements for shaping the transformation efforts of Lilly USA LLC to become a more data-driven and customer-centric organisation. This transformation applies to both traditional advertising channels and the innovative digital realms related to eCommerce and virtual care.
“In an era where data is the lifeblood of the pharmaceutical industry, the shift towards embracing technology and fortifying cybersecurity measures is not just a strategic move but a critical imperative. As we navigate this transformative landscape, these cybersecurity-related roles serve as the guardians of our digital future, ensuring privacy, compliance, and resilience in the face of evolving challenges” concluded Singh.
- Published On Sep 4, 2023 at 02:09 PM IST
Join the community of 2M+ industry professionals
Subscribe to our newsletter to get latest insights & analysis.
Download ETHealthworld App
- Get Realtime updates
- Save your favourite articles
Scan to download App
No Byline Policy
Editorial Guidelines
Corrections Policy
Source